Vaxcyte Statistics
Total Valuation
Vaxcyte has a market cap or net worth of $10.50 billion. The enterprise value is $9.43 billion.
| Market Cap | 10.50B |
| Enterprise Value | 9.43B |
Important Dates
The last earnings date was Wednesday, November 4, 2026, after market close.
| Earnings Date | Nov 4, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Vaxcyte has 158.30 million shares outstanding. The number of shares has increased by 4.85% in one year.
| Current Share Class | 158.30M |
| Shares Outstanding | 158.30M |
| Shares Change (YoY) | +4.85% |
| Shares Change (QoQ) | +3.05% |
| Owned by Insiders (%) | 0.59% |
| Owned by Institutions (%) | 104.07% |
| Float | 145.89M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 3.98 |
| P/TBV Ratio | 4.22 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.56, with a Debt / Equity ratio of 0.09.
| Current Ratio | 4.56 |
| Quick Ratio | 4.37 |
| Debt / Equity | 0.09 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -42.68% and return on invested capital (ROIC) is -27.05%.
| Return on Equity (ROE) | -42.68% |
| Return on Assets (ROA) | -24.98% |
| Return on Invested Capital (ROIC) | -27.05% |
| Return on Capital Employed (ROCE) | -45.71% |
| Weighted Average Cost of Capital (WACC) | 11.11% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.27M |
| Employee Count | 507 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +59.33% in the last 52 weeks. The beta is 1.29, so Vaxcyte's price volatility has been higher than the market average.
| Beta (5Y) | 1.29 |
| 52-Week Price Change | +59.33% |
| 50-Day Moving Average | 61.97 |
| 200-Day Moving Average | 57.51 |
| Relative Strength Index (RSI) | 56.04 |
| Average Volume (20 Days) | 2,089,251 |
Short Selling Information
The latest short interest is 14.62 million, so 9.24% of the outstanding shares have been sold short.
| Short Interest | 14.62M |
| Short Previous Month | 17.29M |
| Short % of Shares Out | 9.24% |
| Short % of Float | 10.02% |
| Short Ratio (days to cover) | 4.40 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -1.23B |
| Pretax Income | -1.15B |
| Net Income | -1.15B |
| EBITDA | -1.21B |
| EBIT | -1.23B |
| Earnings Per Share (EPS) | -$8.07 |
Balance Sheet
The company has $1.29 billion in cash and $221.84 million in debt, with a net cash position of $1.07 billion or $6.76 per share.
| Cash & Cash Equivalents | 1.29B |
| Total Debt | 221.84M |
| Net Cash | 1.07B |
| Net Cash Per Share | $6.76 |
| Equity (Book Value) | 2.49B |
| Book Value Per Share | 16.67 |
| Working Capital | 1.05B |
Cash Flow
In the last 12 months, operating cash flow was -$962.01 million and capital expenditures -$32.75 million, giving a free cash flow of -$994.76 million.
| Operating Cash Flow | -962.01M |
| Capital Expenditures | -32.75M |
| Depreciation & Amortization | 23.33M |
| Net Borrowing | n/a |
| Free Cash Flow | -994.76M |
| FCF Per Share | -$6.28 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Vaxcyte does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -4.85% |
| Shareholder Yield | -4.85% |
| Earnings Yield | -12.16% |
| FCF Yield | -9.47% |
Analyst Forecast
The average price target for Vaxcyte is $117.20, which is 76.61% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $117.20 |
| Price Target Difference | 76.61% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 11 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |